MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR - News) today announced that it received notice from the Securities and Exchange Commission (SEC) that the investigation concerning the company’s historical stock option granting practices has been completed and that no enforcement action was recommended.
About Sepracor
Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving unmet medical needs. Sepracor’s drug development program has yielded a portfolio of pharmaceutical products and candidates with a focus on respiratory and central nervous system disorders. Sepracor’s corporate headquarters are located in Marlborough, Massachusetts.
For a copy of this release or any recent release,
visit Sepracor’s web site at www.sepracor.com.
Contact: Sepracor Inc. David P. Southwell, 508-481-6700 Chief Financial Officer or Jonae R. Barnes, 508-481-6700 Sr. Vice President Investor Relations
Source: Sepracor Inc.
